Phase I Safety and Pharmacokinetic Trials of 1263W94, a Novel Oral Anti-Human Cytomegalovirus Agent, in Healthy and Human Immunodeficiency Virus-Infected Subjects

1263W94 [maribavir; 5,6-dichloro-2-(isopropylamino)-1, β-l-ribofuranosyl-1-H-benzimidazole], a novel benzimidazole compound, has been demonstrated to potently and selectively inhibit human cytomegalovirus replication in vitro and to have favorable safety profiles in animal species. Two phase I trial...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wang, Laurene H., Peck, Richard W., Yin, Yin, Allanson, Jane, Wiggs, Rebecca, Wire, Mary Beth
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2003
Gaiak:
Antiviral Agents
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC152490/
https://ncbi.nlm.nih.gov/pubmed/12654667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.47.4.1334-1342.2003
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak